VRCI.LSE Verici Dx Plc

Healthcare Biotechnology London Exchange
0.0023 GBX
Close of Nov 3, 2026
0.1943 0.9790
Market cap
GBX 15.2M
P/E
-
P/B
3.59x
ROE
-275.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is VRCI.LSE undervalued?

Graham number

The Graham number of Verici Dx Plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Verici Dx Plc fundamental analysis

No fundamental analysis for Verici Dx Plc yet.

Verici Dx Plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Verici Dx Plc

Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; Clarava, a pre-transplant prognosis test for the risk of early acute rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failur…

Full company profile